Financial Daily from THE HINDU group of publications
Friday, Aug 15, 2003
Financial Daily from THE HINDU group of publications Friday, Aug 15, 2003 |
|
|
|
|
|
Corporate
-
Announcements Ranbaxy gets US nod for Amoxicillin Our Bureau
New Delhi , Aug 14 PHARMA major Ranbaxy Laboratories Ltd has received the green signal from the US regulatory authority to market its new dosage form of Amoxicillin, which is used to target bacterial infections in children. The company said that it had received approval from the US Food and Drug Administration to market DisperMox, which is Ranbaxy's brand of Amoxicillin tablets. The clearance is for the oral suspension form in 200 mg and 400 mg strengths, according to a company communiqué. The Amoxicillin suspensions/chewable tablet market is estimated to be in excess of $105.7 million in the US. DisperMox is the generic version of GlaxoSmithKline's Amoxil and will be launched in the US by October 2003 and will be marketed and distributed by Ranbaxy Pharmaceuticals Inc (RPI), a wholly owned subsidiary of RLL. Market development of this novel dosage form and manufacturing will remain a primary role of Ranbaxy, whereas the sales activities will be outsourced from Blansett Pharmacal Co. (Blansett), Arkansas.
Article E-Mail :: Comment :: Syndication
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | The Sportstar | Frontline | The Hindu eBooks | Home |
Copyright © 2003, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|